Improving the Treatment of Major Depressive Disorder in Older Adults: Clinical Advances and Emerging Therapies
Release Date: March-14-14
Credit Expiration Date: March-14-15
This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older adults with major depressive disorder.
1.0 Contact Hour of ACPE Credit
A CPE-certified online interactive newsletter with highlights from the American Society of Consultant Pharmacists workshop.
An estimated 6.5 million (about 19%) of older adults in the United States suffer from major depressive disorder (MDD), a condition that leads to significant disability and medical comorbidity. In the long-term care setting, up to 35% of older adults suffer from depression. Depression is the most common mental health disorder among older adults. However, MDD is often unrecognized or suboptimally treated in older adults. Numerous antidepressants for the treatment of MDD are available, yet many older adults do not obtain relief from their symptoms because they fail to respond adequately to these medications or experience intolerable side effects. The goal of this continuing education activity is to expand the knowledge, skills, and competency among consultant pharmacists with regard to current and emerging medications for MDD, ultimately improving quality of life for their older adult patients with MDD.
NOTE: This activity was presented on November 22, 2013, in conjunction with ASCP's Annual Meeting and Exhibition.
Lori A. Daiello, PharmD, BCPP
Assistant Professor of Neurology (Research)
Warren Alpert Medical School
Sumer Verma, MD
Associate Clinical Professor Psychiatry
Boston University School of Medicine
Medical Director, Dementia Service Briarwood
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Daiello has no relevant financial conflicts to disclose.
Dr. Verma has no relevant financial conflicts to disclose.
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.
Kathryn Klobnak, medical writer/editor, has no relevant financial conflicts to disclose.
Leslie Sharp, editorial manager, has no relevant financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-14-007-H01-P, has been assigned 1.0 Contact Hour (0.1 CEU).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.
Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.
This activity will take approximately 1 hour to complete.
Supported by an independent educational grant from Forest Pharmaceuticals, Inc.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, or Forest Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.